Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Caladrius Biosciences Inc (NASDAQ:CLBS)

5.15
Delayed Data
As of 3:59pm ET
 -0.22 / -4.10%
Today’s Change
4.01
Today|||52-Week Range
20.30
-52.31%
Year-to-Date
SECTOR
Distribution Services
INDUSTRY
Wholesale Distributors
MARKET CAP
$31.8M

Company Description

Caladrius Biosciences, Inc. operates as a global healthcare company, which engages in developing cellular therapies that repair damaged tissue, cells and organs and restore their normal function. It is pursuing the preservation and enhancement of human health globally through the development of cell based therapeutics that prevent, treat or cure disease. The companies business includes the development of novel proprietary cell therapy products, as well as a revenue-generating contract development and manufacturing service business that it leverages for the development of therapeutics while providing service to other companies in the cell therapy industry developing products. The company was founded in September 1980 and is headquartered in New York, NY.

Contact Information

Caladrius Biosciences, Inc.
106 Allen Road
Basking Ridge New Jersey 07920
P:(908) 842-0100
Investor Relations:

Employees

Shareholders

Other institutional7.50%
Mutual fund holders3.03%
Individual stakeholders1.65%

Top Executives

David J. MazzoChief Executive Officer & Director
Joseph TalamoChief Financial Officer & Senior Vice President
Douglas W. LosordoChief Medical Officer & SVP-Regulatory Affairs
Greg BerkinVice President-Information Technology
Robert A. PretiDirector, Chief Technical Officer & Senior VP